Literature DB >> 11692893

FDA approves Gleevec for leukemia treatment.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692893

Source DB:  PubMed          Journal:  FDA Consum        ISSN: 0362-1332


× No keyword cloud information.
  5 in total

1.  Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements.

Authors:  Chen Ding; Doug W Chan; Wanlin Liu; Mingwei Liu; Dong Li; Lei Song; Chonghua Li; Jianping Jin; Anna Malovannaya; Sung Yun Jung; Bei Zhen; Yi Wang; Jun Qin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-03       Impact factor: 11.205

Review 2.  Data-driven methods to discover molecular determinants of serious adverse drug events.

Authors:  A P Chiang; A J Butte
Journal:  Clin Pharmacol Ther       Date:  2009-01-28       Impact factor: 6.875

3.  Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate.

Authors:  Vasantha Thavaraj; Rachna Seth
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

4.  Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.

Authors:  Alessandra Chiarenza; Fabrizio Manetti; Elena Petricci; Martial Ruat; Antonella Naldini; Maurizio Taddei; Fabio Carraro
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

5.  Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.

Authors:  Houda Boudiaf; Khedaoudj Ezziane; Nassiba Ould Rouis; Meriem Himrane; Saliha Hakem; Hanifa Benchabane; Houria Boukhelal; Radja Arous; Lynda Chikhi
Journal:  Pan Afr Med J       Date:  2020-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.